(Alliance News) - Verici Dx PLC on Monday said that pricing had been finalised for two of its pre- and post-transplant tests, in line with the group's strategy to "develop and commercialise a complementary suite of ground-breaking products". Read More
(Alliance News) - Verici Dx PLC on Monday celebrated the publication of data from its Tutivia trial, which demonstrated the efficacy of the post-transplant test, in the American Journal of Transplantation. Read More
(Alliance News) - Verici Dx PLC on Wednesday said it attained the ISO 27001 certification for its information security management system. Read More
(Alliance News) - Stock prices in London were higher at midday on Wednesday, as investors reacted to a rapid slowdown in the UK annual inflation rate last month, alongside a cooling of US consumer price pressure and favourable data out of China too. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
(Alliance News) - Verici Dx PLC shares jumped on Wednesday after it signed an exclusive global licensing agreement with Thermo Fisher Scientific Inc to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection. Read More
(Alliance News) - The following is a round-up of earning and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Verici Dx PLC on Monday said it received successful results from its clinical study of Clarava that demonstrate it as a test capable of informing a clear, actionable response from clinicians. Read More
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Verici Dx PLC on Thursday said it won two key patents for its RNA signature biomarker tests Tutiva and Clarava in the US. Read More
Verici Dx PLC - Cardiff-based developer of clinical diagnostics for organ transplant - Successfully progresses its registration status to compliance certification to the Centers for Medicare & Medicaid for its commercial clinical operations in 45 US states. This follows the inspection by CMS of the company's US clinical laboratory based in Franklin, Tennessee. Verici Dx will now proceed with its plan towards full accreditation in the remaining five states. Verici Dx explains the milestone of certification is also a key requirement to obtaining insurance reimbursement coverage under Medicare under the local coverage determination application being submitted this year. Company also intends to expand commercialisation of its advanced kidney transplant service offerings, including Tutivia. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Rebrands its post-transplant blood test focused on acute rejection, Tuteva, to Tutivia. Tutivia will be the first test commercialised on the Verici transplant biomarker platform, with a soft commercial launch in the US expected later in 2022. Read More
(Alliance News) - Verici Dx PLC on Wednesday reported a widened loss in the first half but the firm said it is geared up for a commercialisation push to start generating revenue. Read More
(Alliance News) - Verici Dx PLC on Tuesday announced the successful outcome of a clinical validation study of its Clarava test. Read More
EKF Diagnostics Holdings PLC - Cardiff-based diagnostics and central laboratory assay maker - Distributes 9.1 million shares in Verici Dx PLC to shareholders through distribution in specie. In March, EKF confirmed it would distribute to its own shareholders shares in Verici it would receive for participating in the clinical diagnostics company's fundraising. Read More
(Alliance News) - Verici Dx PLC on Tuesday reported further data from a clinical validation study evaluating Tuteva, the company's post-transplant blood test focused on acute rejection. Read More